Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
February 18 2022 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), an early
commercial-stage biopharmaceutical company leading a new treatment
paradigm to improve the lives of patients suffering from pruritus,
today announced the Company will host a virtual research and
development (R&D) event on Friday, March 11, 2022, from 1:00 to
2:00 p.m. ET. The presentation will focus on the initiation of oral
difelikefalin Phase 3 programs for the treatment of pruritus in
patients with atopic dermatitis and non-dialysis dependent chronic
kidney disease. An interactive Q&A session will follow the
presentation.
Presenters will include:
- Christopher Posner, President &
Chief Executive Officer and Director of Cara Therapeutics
- Joana Goncalves, MD, Chief Medical
Officer of Cara Therapeutics
- Brian Kim, MD, MTR, Icahn School of
Medicine at Mount Sinai, NY
- Jonathan Silverberg, MD, PhD, MPH,
George Washington University School of Medicine and Health
Sciences
A live audio webcast of the presentation and
accompanying slides will be accessible under “Events &
Presentations” in the News & Investors section of the Company’s
website at www.CaraTherapeutics.com. A replay of the webcast will
be archived on the Company’s website following the
presentation.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s novel KORSUVA™ (difelikefalin) injection is the first and
only FDA-approved treatment for moderate-to-severe pruritus
associated with chronic kidney disease in adults undergoing
hemodialysis. The Company is developing an oral formulation of
difelikefalin and plans to initiate Phase 3 programs in the first
quarter of 2022 for the treatment of pruritus in patients with
atopic dermatitis and non-dialysis-dependent chronic kidney
disease. Phase 2 trials of oral difelikefalin are ongoing in
primary biliary cholangitis and notalgia paresthetica patients with
moderate-to-severe pruritus. For more information, visit
www.CaraTherapeutics.com and follow the company on Twitter,
LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Oct 2023 to Oct 2024